GGrantIndex
← Leaderboards

Paul R Conlin

Brigham And Women'S Hospital

$6,611,270
Attributed
$6,611,270
Total exposure
10
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.3M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$6,611,270 · 8
VA$0 · 2

By mechanism

R01$4,052,095 · 2
K24$1,730,684 · 1
M01$828,491 · 5
I01$0 · 2

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Characteristics

Research focus

CharacteristicsAffectBlood PressureClinical TrialsCaringDiabetes MellitusRisk FactorsKidney DiseasesClinical ResearchPatternAfrican AmericanEquilibriumGlycosylated Hemoglobin AProviderComplexCardiovascular DiseasesBlood Glucose RegulationInterestComplications Of Diabetes MellitusEventMortalityBenefits And RisksClinical Practice GuidelineCardiovascular Disorder Risk

Grant awards (37)

Comparative and cost effectiveness of diabetes medications$0
I01 · FY2025 · VA · contact PI
Comparative and cost effectiveness of diabetes medications$0
I01 · FY2024 · VA · contact PI
Comparative and cost effectiveness of diabetes medications$0
I01 · FY2023 · VA · contact PI
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications$257,848
R01 · FY2022 · DK · contact PI
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications$252,243
R01 · FY2022 · DK · contact PI
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications$188,771
R01 · FY2022 · DK · contact PI
Comparative and cost effectiveness of diabetes medications$0
I01 · FY2022 · VA · contact PI
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications$520,406
R01 · FY2021 · DK · contact PI
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications$520,406
R01 · FY2020 · DK · contact PI
Hemoglobin A1C Variability as a Risk Factor for Diabetes Complications$590,922
R01 · FY2019 · DK · contact PI
Hemoglobin A1c Variability and Adverse Health Outcomes$0
I01 · FY2019 · VA · contact PI
Hemoglobin A1c Variability and Adverse Health Outcomes$0
I01 · FY2018 · VA · contact PI
Hemoglobin A1c Variability and Adverse Health Outcomes$0
I01 · FY2018 · VA · contact PI
Renal blood flow, vascular stiffness, and the DASH diet$197,394
K24 · FY2012 · DK · contact PI
Renal blood flow, vascular stiffness, and the DASH diet$197,394
K24 · FY2011 · DK · contact PI
Renal blood flow, vascular stiffness, and the DASH diet$197,394
K24 · FY2010 · DK · contact PI
Cardiovascular and renal hemodynamics and the DASH diet$347,562
R01 · FY2009 · HL · contact PI
Renal blood flow, vascular stiffness, and the DASH diet$197,394
K24 · FY2009 · DK · contact PI
Renal blood flow, vascular stiffness, and the DASH diet$193,458
K24 · FY2008 · DK · contact PI
CARDIOVASCULAR AND RENAL HEMODYNAMICS AND THE DASH DIET$104,960
M01 · FY2008 · RR · contact PI
CARDIOVASCULAR AND RENAL HEMODYNAMICS AND THE DASH DIET$703,461
M01 · FY2007 · RR · contact PI
Cardiovascular and renal hemodynamics and the DASH diet$456,440
R01 · FY2007 · HL · contact PI
Renal blood flow,sodium handling and the DASH diet$149,530
K24 · FY2007 · DK · contact PI
Cardiovascular and renal hemodynamics and the DASH diet$459,792
R01 · FY2006 · HL · contact PI
Renal blood flow,sodium handling and the DASH diet$149,530
K24 · FY2006 · DK · contact PI
Cardiovascular and renal hemodynamics and the DASH diet$457,705
R01 · FY2005 · HL
Renal blood flow,sodium handling and the DASH diet$149,530
K24 · FY2005 · DK
ASSESSMENT OF DIASTOLIC FUNCTION AND CENTRAL AORTIC STIFFNESS$18,755
M01 · FY2005 · RR
Renal blood flow,sodium handling and the DASH diet$149,530
K24 · FY2004 · DK
Assessment of Diastolic Function /Central Aortic Stiffne$1,315
M01 · FY2004 · RR
Renal blood flow,sodium handling and the DASH diet$149,530
K24 · FY2003 · DK
EPLERENONE &LOSARTAN IN LOW RENIN HYPERTENSION$0
M01 · FY2002 · RR
TEVETEN PLUS ENALAPRIL VERSUS PLACEBO IN AFRICAN AMERICAN PATIENTS W/HYPERTENSION$0
M01 · FY2002 · RR
EPLERENONE &LOSARTAN IN LOW RENIN HYPERTENSION$0
M01 · FY2001 · RR
TEVETEN PLUS ENALAPRIL VERSUS PLACEBO IN AFRICAN AMERICAN PATIENTS W/HYPERTENSION$0
M01 · FY2001 · RR
EPLERENONE &LOSARTAN IN LOW RENIN HYPERTENSION$0
M01 · FY2000 · RR
TEVETEN PLUS ENALAPRIL VERSUS PLACEBO IN AFRICAN AMERICAN PATIENTS W/HYPERTENSION$0
M01 · FY2000 · RR